Presentation is loading. Please wait.

Presentation is loading. Please wait.

Module 12 Bloodborne Pathogens and the Dental Health Care Worker.

Similar presentations


Presentation on theme: "Module 12 Bloodborne Pathogens and the Dental Health Care Worker."— Presentation transcript:

1

2 Module 12 Bloodborne Pathogens and the Dental Health Care Worker

3 Christine Wisnom, RN, BS Nurse Educator Dental School University of Maryland Baltimore Helene Bednarsh, RDH, MPH Director, HIV Dental Ombudsperson Program Boston Public Health Commission Kathy Eklund, RDH, MPH The Forsyth Institute Boston, Massachusetts Christine Wisnom, RN, BS Nurse Educator Dental School University of Maryland Baltimore Helene Bednarsh, RDH, MPH Director, HIV Dental Ombudsperson Program Boston Public Health Commission Kathy Eklund, RDH, MPH The Forsyth Institute Boston, Massachusetts

4 Updated Postexposure Protocols for HBV, HCV, HIV & Special Circumstances MMWR, CDC, 6-01,Vol. 50,RR-11 HIV Hepatitis C Hepatitis B Pregnancy Delayed exposure report Unknown donor exposure Source patient drug resistant Human bite protocols HIV Hepatitis C Hepatitis B Pregnancy Delayed exposure report Unknown donor exposure Source patient drug resistant Human bite protocols

5 Objectives Categories  Prevention  Planning  Identification  Implementation  Evaluation  Prevention  Planning  Identification  Implementation  Evaluation

6 Objectives-Prevention  Prevention is best strategy to avoid infection  Prevent HBV infection by HBV vaccine  Prevent HBV transmission by HBV PEP  Prevent HIV infection by timely HIV PEP  Prevent injury through utilization of “safe sharps”, auto-recapping devices  Prevention is best strategy to avoid infection  Prevent HBV infection by HBV vaccine  Prevent HBV transmission by HBV PEP  Prevent HIV infection by timely HIV PEP  Prevent injury through utilization of “safe sharps”, auto-recapping devices

7 Safe Sharps Management

8 Objectives- Planning  Planning prior to occupational exposure is the key to efficient implementation of post-exposure protocols  Establish a protocol for occupational exposures  Educate health care workers regarding the implementation of the plan during job orientation and ongoing job training. CDC, MMWR , Vol.50/No. RR-11, 16.  Planning prior to occupational exposure is the key to efficient implementation of post-exposure protocols  Establish a protocol for occupational exposures  Educate health care workers regarding the implementation of the plan during job orientation and ongoing job training. CDC, MMWR , Vol.50/No. RR-11, 16.

9 Objectives- Identification  Identify:  Potential risk factors for transmission of HIV, HBV and HCV  Health Care Professional (HCP) for medical follow-up  Various recommendations for PEP based upon type of exposure for each  Identify:  Potential risk factors for transmission of HIV, HBV and HCV  Health Care Professional (HCP) for medical follow-up  Various recommendations for PEP based upon type of exposure for each

10 Objectives- Implementation  Implement :Methods of risk reduction based on Work Practice Controls (WPC) & Exposure Controls (EC)  Emergency first aid for injury  Post-exposure counseling  Prophylaxis  Medical evaluation and follow-up of exposed individuals  Implement :Methods of risk reduction based on Work Practice Controls (WPC) & Exposure Controls (EC)  Emergency first aid for injury  Post-exposure counseling  Prophylaxis  Medical evaluation and follow-up of exposed individuals

11 Objectives- Evaluation  Evaluate:  The effectiveness of the Occupational Exposure Monitoring System  Adapt any necessary modifications for improvement  Continue to maintain an evolving system based upon current scientific findings  Evaluate:  The effectiveness of the Occupational Exposure Monitoring System  Adapt any necessary modifications for improvement  Continue to maintain an evolving system based upon current scientific findings

12 Exposure Definition “An exposure is a percutaneous injury (e.g., a needle stick or cut with a sharp object) or contact of mucous membrane or nonintact skin (e.g., exposed skin that is chapped, abraded, or afflicted with dermatitis) with blood, tissue, or other body fluids that are potentially infectious.” CDC, MMWR , Vol. 50/No. RR-11, 3. “An exposure is a percutaneous injury (e.g., a needle stick or cut with a sharp object) or contact of mucous membrane or nonintact skin (e.g., exposed skin that is chapped, abraded, or afflicted with dermatitis) with blood, tissue, or other body fluids that are potentially infectious.” CDC, MMWR , Vol. 50/No. RR-11, 3.

13 Infectious Body Fluids “In addition to blood and body fluids containing visible blood, semen and vaginal secretions are also considered potentially infectious. Although semen and vaginal secretions have been implicated in sexual transmission of HBV, HCV and HIV, they have not caused occupational transmission from patient to health care worker.” CDC, MMWR , Vol. 50/No. RR-11, 3. “In addition to blood and body fluids containing visible blood, semen and vaginal secretions are also considered potentially infectious. Although semen and vaginal secretions have been implicated in sexual transmission of HBV, HCV and HIV, they have not caused occupational transmission from patient to health care worker.” CDC, MMWR , Vol. 50/No. RR-11, 3.

14 Potentially Infectious Fluids  The risk for transmission of HIV, HBV and HCV with the following body fluids is unknown, caution is recommended when handling : cerebrospinal fluid, synovial fluid, pleural fluid, peritoneal fluid, pericardial fluid, and amniotic fluid. They are considered to pose a potential risk for transmission. CDC, MMWR , Vol. 50/No. RR-11, 3.  The risk for transmission of HIV, HBV and HCV with the following body fluids is unknown, caution is recommended when handling : cerebrospinal fluid, synovial fluid, pleural fluid, peritoneal fluid, pericardial fluid, and amniotic fluid. They are considered to pose a potential risk for transmission. CDC, MMWR , Vol. 50/No. RR-11, 3.

15 Low/No Risk Body Fluids “Feces, nasal secretions, saliva, sputum, sweat, tears, urine and vomitus are not considered potentially infectious unless they contain blood. The risk for transmission of HBV. HCV and HIV infection from these fluids and materials is extremely low.” Caution is recommended when handling these fluids. CDC, MMWR , Vol. 50/No. RR-11, 3. “Feces, nasal secretions, saliva, sputum, sweat, tears, urine and vomitus are not considered potentially infectious unless they contain blood. The risk for transmission of HBV. HCV and HIV infection from these fluids and materials is extremely low.” Caution is recommended when handling these fluids. CDC, MMWR , Vol. 50/No. RR-11, 3.

16 Saliva Infectious for HIV? However, caution is recommended when handling.  In the absence of visible blood in the saliva, exposure to saliva from a person infected with HIV is not considered a potential risk for HIV transmission. However, caution is recommended when handling. CDC, MMWR , Vol. 50/No. RR-11, 3. However, caution is recommended when handling.  In the absence of visible blood in the saliva, exposure to saliva from a person infected with HIV is not considered a potential risk for HIV transmission. However, caution is recommended when handling. CDC, MMWR , Vol. 50/No. RR-11, 3.

17 Occupational Transmission of HCV Transmission from mucous membrane exposure to blood rarely occurs. HCV is not transmitted efficiently through occupational exposure to blood. Following percutaneous injury from HCV+ source infection rate is 1.8% (range 0%-7%). No transmission has been documented from nonintact or intact skin contact with HCV+ blood. CDC, MMWR, , Vol. 50/ No. RR-11, 5 Transmission from mucous membrane exposure to blood rarely occurs. HCV is not transmitted efficiently through occupational exposure to blood. Following percutaneous injury from HCV+ source infection rate is 1.8% (range 0%-7%). No transmission has been documented from nonintact or intact skin contact with HCV+ blood. CDC, MMWR, , Vol. 50/ No. RR-11, 5

18 Survival of HBV in the Environment Only 1/2 of all HBV positive HCW’s recall having an occupational injury. (DIRECT) Many infected individuals can recall caring for HBV+ patients. (INDIRECT) HBV can survive in dried blood at room temperature on environmental surfaces for at least 1 week. Exposures have occurred via scratches, abrasions, burns or on mucosal surfaces with poor infection control. Evidence of outbreaks have occurred in Hemodialysis Units. CDC, MMWR , Vol. 50/No. RR-11, 4

19 Occupational Transmission of HBV The risk of HBV transmission following needle stick is directly related to the amount of blood and the HBeAg status of the patient. Infection from HBeAg+ & HBsAg+ is: 37-62% Infection from HBeAg- & HBsAg+ is: 23-37% CDC, MMWR , Vol. 50/No. RR-11, 3. The risk of HBV transmission following needle stick is directly related to the amount of blood and the HBeAg status of the patient. Infection from HBeAg+ & HBsAg+ is: 37-62% Infection from HBeAg- & HBsAg+ is: 23-37% CDC, MMWR , Vol. 50/No. RR-11, 3.

20 Post-Hepatitis B Vaccine Testing “Health Care Professionals who have contact with patients or blood and are at ongoing risk for percutaneous injuries should be tested 1-2 months after completion of the 3-dose vaccination series for anti-HBs.” Hepatitis B vaccine may be given during pregnancy, contains no infectious particles. CDC, MMWR /Vol. 50/No. RR-11, 16. “Health Care Professionals who have contact with patients or blood and are at ongoing risk for percutaneous injuries should be tested 1-2 months after completion of the 3-dose vaccination series for anti-HBs.” Hepatitis B vaccine may be given during pregnancy, contains no infectious particles. CDC, MMWR /Vol. 50/No. RR-11, 16.

21 Nonresponders to HBV Vaccine People who do not respond to the first three vaccine series <10 mIU/ml should complete a 2 nd, 3 vaccine series. People who do not respond to the first HBV series only have a 30-50% chance of responding to the 2 nd series. Testing at completion should be done to determine efficacy/or HbsAg status. CDC, MMWR , Vol. 50/No. RR-11, 16. People who do not respond to the first three vaccine series <10 mIU/ml should complete a 2 nd, 3 vaccine series. People who do not respond to the first HBV series only have a 30-50% chance of responding to the 2 nd series. Testing at completion should be done to determine efficacy/or HbsAg status. CDC, MMWR , Vol. 50/No. RR-11, 16.

22 PEP for HBV Exposures in Non-vaccinated HCW’s  Health care workers who experience occupational exposure to the blood or body fluids of an HBsAg + individual should receive –1 dose, 0.06mL/kg., of Hepatitis B immune globulin (HBIG), and –The 1 st dose of the HBV vaccine series.  Health care workers who experience occupational exposure to the blood or body fluids of an HBsAg + individual should receive –1 dose, 0.06mL/kg., of Hepatitis B immune globulin (HBIG), and –The 1 st dose of the HBV vaccine series.

23 PEP for HBV Non-responders  When a person has not responded to the 1 st HBV vaccine series & is exposed to the blood or body fluids of an HBsAg positive patient, a single dose of HBIG, preferably within 24 hrs. after exposure, and the first dose of the 2 nd HBV vaccine series is preferred.  CDC, MMWR. Vol. 50/ No. RR-11, 4.  When a person has not responded to the 1 st HBV vaccine series & is exposed to the blood or body fluids of an HBsAg positive patient, a single dose of HBIG, preferably within 24 hrs. after exposure, and the first dose of the 2 nd HBV vaccine series is preferred.  CDC, MMWR. Vol. 50/ No. RR-11, 4.

24 PEP for HBV for Non-responders  HCW’s that experience occupational exposures to the blood or body fluids of HBsAg positive patients who are non- responders to both the 1 st and 2 nd HBV vaccine series should receive 2 doses of HBIG. –One at the time of injury and the 2 nd dose 1 month later. – HBIG should be given with 24 hrs. if possible. –When given in less than 7 days the effectiveness is approximately 75%. When given in > 7days after exposure effectiveness is uncertain. CDC, MMWR , Vol50/No. RR-11, 4  HCW’s that experience occupational exposures to the blood or body fluids of HBsAg positive patients who are non- responders to both the 1 st and 2 nd HBV vaccine series should receive 2 doses of HBIG. –One at the time of injury and the 2 nd dose 1 month later. – HBIG should be given with 24 hrs. if possible. –When given in less than 7 days the effectiveness is approximately 75%. When given in > 7days after exposure effectiveness is uncertain. CDC, MMWR , Vol50/No. RR-11, 4

25 Expert Consultation Advised  When drug resistance is evident  HCW is pregnant  Source is unknown  Source is high risk for HIV infection  When drug resistance is evident  HCW is pregnant  Source is unknown  Source is high risk for HIV infection

26 Use of PEP When Source is Unknown Decision made case-by-case  PPE worn, removes 50% of inoculum Type: puncture, splash, laceration Severity : deep wound vs. superficial Body fluid and quantity: blood, saliva, large amount vs. minimal amount of body fluid Decision made case-by-case  PPE worn, removes 50% of inoculum Type: puncture, splash, laceration Severity : deep wound vs. superficial Body fluid and quantity: blood, saliva, large amount vs. minimal amount of body fluid

27 Use of PEP When Source is Unknown (Cont) Environment : IDU clinic, shelter, community prevalence, etc. To treat: a 2 drug PEP for 4 weeks, reevaluate if new information is available, if negative discontinue medications. Do not test discarded needles for bloodborne pathogens. Environment : IDU clinic, shelter, community prevalence, etc. To treat: a 2 drug PEP for 4 weeks, reevaluate if new information is available, if negative discontinue medications. Do not test discarded needles for bloodborne pathogens.

28 Factors that Increase the Probability of HIV Infection Exposure to a larger quantity of blood Injury with a device with visible blood Deep injury Injury with device placed in vein/artery Injury to blood from patient with advanced AIDS Host defense, immune response may prevent infection Exposure to a larger quantity of blood Injury with a device with visible blood Deep injury Injury with device placed in vein/artery Injury to blood from patient with advanced AIDS Host defense, immune response may prevent infection

29 Management of Occupational Blood Exposure When an exposure occurs, you should stop immediately Wash wound with soap & water; flush mucous membranes with water. Antiseptic use and/or bleeding the wound have not been proven to reduce infections.  However, antiseptic use is not contraindicated.  Bleach & other caustic agents should not be poured directly into the wound. When an exposure occurs, you should stop immediately Wash wound with soap & water; flush mucous membranes with water. Antiseptic use and/or bleeding the wound have not been proven to reduce infections.  However, antiseptic use is not contraindicated.  Bleach & other caustic agents should not be poured directly into the wound.

30 Evaluation of Occupational Exposure Obtain informed consent. Test source for HBsAg, anti-HCV, and HIV antibody. Consider using a rapid HIV antibody test if available. For patients who refuse testing/or unknown patients, consider medical diagnosis, risk behaviors and S/S. Do not test discarded needles for bloodborne pathogens. Obtain informed consent. Test source for HBsAg, anti-HCV, and HIV antibody. Consider using a rapid HIV antibody test if available. For patients who refuse testing/or unknown patients, consider medical diagnosis, risk behaviors and S/S. Do not test discarded needles for bloodborne pathogens.

31 HCV Exposures Following occupational injury on an HCV+ patient: Perform baseline & F/U testing for anti-HCV and alanine aminotransferase (ALT) 4-6 months after exposure. Perform HCV RNA 4-6 weeks after exposure, to determine active viral replication. Confirm repeatedly positive anti-HCV (EIAs) with additional tests. No vaccine or PEP are available for protection against HCV. IG is not recommended for PEP. Following occupational injury on an HCV+ patient: Perform baseline & F/U testing for anti-HCV and alanine aminotransferase (ALT) 4-6 months after exposure. Perform HCV RNA 4-6 weeks after exposure, to determine active viral replication. Confirm repeatedly positive anti-HCV (EIAs) with additional tests. No vaccine or PEP are available for protection against HCV. IG is not recommended for PEP.

32 Treating early HCV disease  While there is currently no vaccine to prevent HCV infection, or PEP to prevent infection immediately following exposure, recent studies suggest that early treatment of acute HCV may prevent chronic infection.  Therefore HCW’s should be vigilant with recommendations for follow-up and testing.  While there is currently no vaccine to prevent HCV infection, or PEP to prevent infection immediately following exposure, recent studies suggest that early treatment of acute HCV may prevent chronic infection.  Therefore HCW’s should be vigilant with recommendations for follow-up and testing.

33 Health Care Professional (HCP) Recommendations for PEP in HIV+ Source  When an exposure occurs on an HIV+ patient a HCP will: –Establish patients’stage of infection: HIV+ or AIDS –Obtain recent blood tests: CD4 cells, T-cell count, viral load & current medications –Determine if donor patient has a resistant strain –If information is not available, initiate PEP  PEP should be initiated even if the exposure exceeds 36 hours  When an exposure occurs on an HIV+ patient a HCP will: –Establish patients’stage of infection: HIV+ or AIDS –Obtain recent blood tests: CD4 cells, T-cell count, viral load & current medications –Determine if donor patient has a resistant strain –If information is not available, initiate PEP  PEP should be initiated even if the exposure exceeds 36 hours

34 Evaluation of HIV Exposure Following exposure on an HIV+ patient, assess and treat HCW, ideally within 2 hours. Perform HIV antibody testing for at least 6 months postexposure.  Baseline  6 weeks  3 months and  6 months. Following exposure on an HIV+ patient, assess and treat HCW, ideally within 2 hours. Perform HIV antibody testing for at least 6 months postexposure.  Baseline  6 weeks  3 months and  6 months.

35 Evaluation of HIV Exposure If symptoms of acute retroviral syndrome appear test HIV antibody immediately.  Advise to use precautions to prevent secondary transmission. Evaluate for side effects at 72 hours and every 2 week thereafter. Treat for 4 weeks. Consider the use of rapid testing. If symptoms of acute retroviral syndrome appear test HIV antibody immediately.  Advise to use precautions to prevent secondary transmission. Evaluate for side effects at 72 hours and every 2 week thereafter. Treat for 4 weeks. Consider the use of rapid testing.

36 Basic PEP for HIV Exposures Basic Regimen (2 drugs): Zidovudine (AZT) & Lamivudine (3TC) available as COMBIVIR. ZDV: 600 mg/day, in 2 or 3 divided doses & 3TC: 150mg twice daily, or give as one COMBIVIR tab twice daily for 4 weeks. Serious toxicity is rare, side effects are manageable, documented to reduce infection by approximately 81%. CDC, MMWR, , Vol. 50/No. RR-11, 9. Other basic 2 drug regimens include: 3TC & Stavudine (d4T); or d4T & Didanosine (ddl), and should be considered in areas of the country where COMBIVIR resistance is common. CDC,MMWR, , Vol. 50/No. RR-11, 10. Basic Regimen (2 drugs): Zidovudine (AZT) & Lamivudine (3TC) available as COMBIVIR. ZDV: 600 mg/day, in 2 or 3 divided doses & 3TC: 150mg twice daily, or give as one COMBIVIR tab twice daily for 4 weeks. Serious toxicity is rare, side effects are manageable, documented to reduce infection by approximately 81%. CDC, MMWR, , Vol. 50/No. RR-11, 9. Other basic 2 drug regimens include: 3TC & Stavudine (d4T); or d4T & Didanosine (ddl), and should be considered in areas of the country where COMBIVIR resistance is common. CDC,MMWR, , Vol. 50/No. RR-11, 10.

37 Expanded PEP for HIV Exposures  An expanded 3 drug regimen should be considered for exposures that pose an increased risk for infection. –A 3 drug regimen includes a basic 2 drug regime plus the addition of a Protease Inhibitor. Bartlett J J. Hopkins Univ. School of Medicine, Medical Management of the HIV Infection, 66.  An expanded 3 drug regimen should be considered for exposures that pose an increased risk for infection. –A 3 drug regimen includes a basic 2 drug regime plus the addition of a Protease Inhibitor. Bartlett J J. Hopkins Univ. School of Medicine, Medical Management of the HIV Infection, 66.

38 HIV PEP for Percutaneous Injuries Exposure Low Risk- Asymptomatic VL High Risk-AIDS Symptomatic, AIDS or VL Unknown Not severe, superficial or injury with solid needle or instrument 2 drug PEP3 drug PEPUsually none, *consider 2 drug PEP Severe, blood on device, deep wound 3 drug PEP Usually none, *consider 2 drug PEP Patient Status VL- Viral load, low 1,500c/ml * Consider if source is high HIV risk

39 HIV PEP for Non-intact Skin & Mucous Membrane Exposures Exposure Low Risk- VL, Asymptomatic High Risk- VL AIDS, blood on instrument Unknown Small volume (drops) Consider 2 drug PEP 2 drug PEPUsually none, consider 2 drug PEP* Large volume, major spill 2 drug PEP3 drug PEPUsually none, consider 2 drug PEP* Patient Status VL-Viral load, low 1,500 c/ml. * Consider if source has HIV risk

40 Risk of HIV Infection Following Percutaneous Exposure to HIV+ Blood For a mucous membrane exposure  0.09% For a percutaneous exposure risk  0.3%. For nonintact skin  < 0.09% For a mucous membrane exposure  0.09% For a percutaneous exposure risk  0.3%. For nonintact skin  < 0.09%

41 Management of HIV Negative Exposure  “If source person is HIV seronegative and has no clinical evidence of AIDS or symptoms of HIV infection, no further testing of the person for HIV infection is indicated.  The likelihood of the source person being in the “window period” of HIV, in the absence of acute retroviral syndrome, is extremely small.”  “If source person is HIV seronegative and has no clinical evidence of AIDS or symptoms of HIV infection, no further testing of the person for HIV infection is indicated.  The likelihood of the source person being in the “window period” of HIV, in the absence of acute retroviral syndrome, is extremely small.”

42 Management of Human Bites  Evaluation of human bites must include both the person who is bitten and the person who inflicted the bite, since both parties were potentially exposed to the other persons blood.  All counseling, testing, PEP and follow-up must be conducted on both parties for HIV, HBV & HCV.

43 Surveillance of Health Care Workers with HIV/AIDS, June 30, 2001 Ref: CDC Natl. Center for HIV, STD and TB Prevention  Through 6/30/01, 23,473 adults with AIDS reported working in health care. This represents 5.1% of the 561,495 reported cases.  Physicians 1,746Therapists 1,042  Surgeons 117Health Aids 5,222  Nurses 5,105Maintenance workers &  Dental workers 482Administrative staff  Paramedics 453  Technicians 3,046  Through 6/30/01, 23,473 adults with AIDS reported working in health care. This represents 5.1% of the 561,495 reported cases.  Physicians 1,746Therapists 1,042  Surgeons 117Health Aids 5,222  Nurses 5,105Maintenance workers &  Dental workers 482Administrative staff  Paramedics 453  Technicians 3,046

44 Surveillance of Health Care Workers with HIV/AIDS, June 30, 2001 Ref: CDC Natl. Center for HIV, STD and TB Prevention  Fifty-seven health care workers in the U. S. have seroconverted to HIV following occupational exposures. Twenty-six have AIDS.  Laboratory workers 19 (16 clinical labs)  Nurses 24  Physicians 6  Surgical technicians 2  Dialysis technicians 1  Respiratory therapist 1  Health aide 1  Embalmer 1  Housekeepers 2  Fifty-seven health care workers in the U. S. have seroconverted to HIV following occupational exposures. Twenty-six have AIDS.  Laboratory workers 19 (16 clinical labs)  Nurses 24  Physicians 6  Surgical technicians 2  Dialysis technicians 1  Respiratory therapist 1  Health aide 1  Embalmer 1  Housekeepers 2

45 Surveillance of Health Care Workers with HIV/AIDS, June 30, 2001 Ref: CDC Natl. Center for HIV, STD and TB Prevention Types of Injuries  Percutaneous 48 (puncture or cut)  Mucotaneous 5 (mucous membrane and/or skin)  Percutaneous & Mucotaneous 2  Unknown 2 Types of Injuries  Percutaneous 48 (puncture or cut)  Mucotaneous 5 (mucous membrane and/or skin)  Percutaneous & Mucotaneous 2  Unknown 2 Body Fluids  Blood 49  Concentrated virus in a laboratory 3  Visibly bloody fluid 1  Unspecified fluids 4

46 Occupational Exposure Assessment Criteria Type of exposure  Percutaneous  Mucous membrane  Nonintact skin  Bites with blood contamination to either person Type of exposure  Percutaneous  Mucous membrane  Nonintact skin  Bites with blood contamination to either person Type & Amount of fluid  Blood  Fluids containing blood  Potentially infectious fluid/tissue, i.e. semen, vaginal secretions, etc.  Direct contact with concentrated virus CDC, MMWR , Vol. 50/ No. RR-11, 17.

47 Occupational Exposure Assessment Criteria Infectious Status of Source  HIV antibody status  HCV antibody status  HBsAg status Infectious Status of Source  HIV antibody status  HCV antibody status  HBsAg status Immune Status of Exposed HCW  HBV, HCV & HIV immune status  Hepatitis B vaccine & vaccine response status CDC, MMWR , Vol. 50/No. RR-11, 18.

48 Occupational Exposure Report  Date & time of injury  Procedure being performed, –If sharp device caused injury, include type, manufacturer & how injury occurred  Type & amount of fluid, severity (deep vs. superficial), condition of skin (chapped, intact)  Source patients HIV, HBV, HCV status & stage (HIV viral load, resistance & antiretroviral meds)  Exposed HCW’s HBV vaccine status & response  Counseling, post-exposure treatment & follow- up CDC, MMWR , Vol. 50/No. RR-11, 17  Date & time of injury  Procedure being performed, –If sharp device caused injury, include type, manufacturer & how injury occurred  Type & amount of fluid, severity (deep vs. superficial), condition of skin (chapped, intact)  Source patients HIV, HBV, HCV status & stage (HIV viral load, resistance & antiretroviral meds)  Exposed HCW’s HBV vaccine status & response  Counseling, post-exposure treatment & follow- up CDC, MMWR , Vol. 50/No. RR-11, 17

49 Occupational Exposure Resources  National Clinicians’ Post-exposure Hotline: PEPline or  CDC, STD, AIDS Hotline: AIDS  Hepatitis Hotline:  CDC reporting for occupationally HIV infected HCW’s & PEP failures:  HIV antiretroviral pregnancy registry:  National Clinicians’ Post-exposure Hotline: PEPline or  CDC, STD, AIDS Hotline: AIDS  Hepatitis Hotline:  CDC reporting for occupationally HIV infected HCW’s & PEP failures:  HIV antiretroviral pregnancy registry:

50 Summary CDC, MMWR , Vol.50 No. RR-11, pp. 3, 6, 7, 9.  Occupational transmission for HIV and HCV is low: –HIV %, HCV- 0- 7%  Occupational transmission for HBsAg+ and HBeAg+ source: –37-62%.  Occupational transmission for HBsAg+ and HBeAg- source: – 23-37%.  Rapid PEP is effective for HIV and HBV: –HIV PEP-81%, HBV PEP –70-75%.  No PEP available for HCV  Standard Precautions, PEP and vaccination are critical components in reducing cross-transmission of bloodborne pathogens.


Download ppt "Module 12 Bloodborne Pathogens and the Dental Health Care Worker."

Similar presentations


Ads by Google